Yields Hit 19-Year Highs, Novo Nordisk Slides, and Cat Products Emerge as Pet Sector Bright Spot

Treasury Yields Push to Highs Not Seen Since 2007

The 10-year Treasury yield held steady around 5.12% on September 24, marking its highest level since July 2007. The move higher came after a 16 basis point surge the prior session, when a weak $70 billion auction of five-year notes met tepid demand and fresh PMI data showed U.S. private sector activity expanding at its fastest pace in more than five years.

Oil prices added fuel. WTI crude rose 2% amid elevated tensions between the U.S. and Iran, and talks at the UN General Assembly made little progress. Higher energy prices are pushing up firms' input costs, according to S&P Global's chief business economist, who noted that fuel and transport costs spiked to the steepest rate in four years during September.

The bond market is now pricing in 70% odds of a Fed rate hike in October, up from 55% a day earlier. The 30-year yield trades above 5.40%. This isn't a rates regime that equity multiples comfortably ignore. Fixed income volatility tends to spill into equity vol, and dealers hedging duration exposure can amplify moves both ways.

Novo Nordisk's Capital Markets Day Falls Flat

Novo Nordisk had a tough week. The Danish pharma giant's Copenhagen-listed shares dropped 7.7% on September 21 after its Capital Markets Day presentation failed to reassure investors. The company set a 2026 to 2030 revenue growth target that merely tracks industry peers, a far cry from the outperformance profile that once justified its premium multiple.

The selloff continued. On the NYSE, the ADR closed at $39.40 on September 22, down 1% that day and off nearly 8% from its pre-event price. By September 23, Copenhagen shares had fallen another 2.53%, bringing the five-day decline to 7.47%. The stock now sits 22% lower year to date.

Novo guided toward more than five potential multi-blockbuster medicines by 2030 and risk-adjusted pipeline sales exceeding 150 billion Danish kroner by 2035. But the market wanted near-term clarity on how Novo would defend its GLP-1 market share against Eli Lilly and a growing cohort of competitors. Shareholders have been pushing for acquisitions to diversify beyond Ozempic. They didn't hear what they wanted.

For options traders, the implied volatility around the event likely got crushed by the post-event drift. Anyone long premium into Capital Markets Day got paid only if they picked the direction.

Cat Ownership Surges, Reshaping Pet Retail Earnings

The pet economy has a new leader: cats. The American Pet Products Association estimated that 53 million households owned a cat in 2025, following a 23% surge in cat ownership in 2024 and another 5% increase last year. Executives attribute the shift to cats' ability to thrive in smaller spaces and their lower care costs relative to dogs.

General Mills reported double-digit percentage growth in cat food sales, including its Tiki Cat brand, while dog food sales dropped by a high single-digit percentage. That divergence left the company's North American pet segment roughly flat year over year. Chewy CEO Sumit Singh summarized the dynamic bluntly on a recent earnings call: dog spending is worsening, cat spending is strengthening.

Petco echoed the trend. The cat product strength is cushioning what would otherwise be a weak quarter for pet retailers navigating a consumer that's watching fuel and grocery prices closely. The cat food market alone is projected to grow from $66 billion in 2026 to nearly $93 billion by 2031, a 7% annualized clip driven by pet humanization and premium nutrition demand.

Meta's Muse Charm Device Lifts Shares 17% This Week

Meta unveiled its Muse Charm device at Meta Connect this week, following the Muse personal agent app launch earlier this month. CEO Mark Zuckerberg offered few specifics on what the gadget will do, but investors didn't seem to care. Meta shares have rallied nearly 17% this week, on track for their biggest weekly gain since early 2024.

The Muse Charm appears to be Meta's bid to get ahead of OpenAI and Google in the consumer AI hardware race. It also reflects the company's ongoing effort to reduce its reliance on Apple for distribution. Meta was late to the generative AI wave initially, and the market is now rewarding its apparent urgency to avoid repeating that mistake.

Options flow on META this week skewed call-heavy, though some of the large prints looked like covered call rolls rather than fresh directional bets. The realized volatility from the 17% move is well above what near-term implied volatility suggested heading into Connect. Anyone who sold straddles into the event learned why event risk isn't always priced efficiently.

What This Means for Positioning

Yields at 5.12% on the 10-year change the math for equity valuations. Duration-sensitive sectors like utilities and REITs face headwinds when risk-free rates offer this kind of competition. Growth stocks with cash flows back-loaded into the future get discounted more heavily. The Fed appears willing to hike again, and the market is adjusting.

Novo Nordisk's slide is a reminder that even dominant franchises face pressure when forward guidance disappoints. The GLP-1 space is crowded and getting more so. Options IV in NVO likely resets lower after this week, but the stock's technical setup looks damaged. Watch the $35 level from earlier this year for potential support.

The cat versus dog divergence in pet retail is a cleaner trade expression than it might appear. Chewy and General Mills have different exposures to the cat segment, and the data suggests that divergence will persist as urban apartment living continues to favor feline companions over canines.